
Scribe Therapeutics
SCTXPro trackingScribe Therapeutics, Inc. · Nasdaq · CRISPR genetic medicines · Research source · 424B4 · Research as of 2026/07/27 · Latest filing · 10-Q · 2026-11-12 SEC ↗ · SEC checked 2026-11-21
Saved research available · 424B4
Scribe Therapeutics priced its initial public offering at $15.00 per share and expects to receive approximately $122.8 million in net proceeds from the IPO and concurrent Sanofi private placement.
Updates and this research have separate source dates; newer facts do not silently replace earlier conclusions.
Newly listed — review valuation, deal quality and post-IPO supply before acting
A clinical-stage biotechnology company developing CRISPR-based genetic medicines. The IPO priced at $15.00 and raised $128.70M.
Full source-backed summary
A clinical-stage biotechnology company developing CRISPR-based genetic medicines. The IPO priced at $15.00 and raised $128.70M. The latest market-value reference is $643.84M; reported revenue is $36.28M and net result is $(35.73M). The offer figures are reconciled to the final prospectus.
- Business and development direction
A clinical-stage biotechnology company developing CRISPR-based genetic medicines.
Current business CRISPR genetic medicines100%
Future development Future direction not yet disclosed
Key risks
Risk 1
Clinical development, regulatory approval and cash-runway outcomes can change the equity value materially.
Risk 2
The latest reported period remains loss-making.
Risk 3
The primary-secondary mix, controlling holders and voting rights require the final beneficial-ownership table.
Sources and calculation notes
Read this report’s SEC filing ↗
| View | Source basis |
|---|---|
| Offering quality | This saved report has no compatible source inputs for this calculation. Open filing ↗ |
| # | Institution | Underwriting allocation | Ratio · calculated | Shares |
|---|---|---|---|---|
| 1 | Leerink Partners LLC | 35.00% | 3,003,000 shares | |
| 2 | Goldman Sachs & Co. LLC | 35.00% | 3,003,000 shares | |
| 3 | Guggenheim Securities, LLC | 18.00% | 1,544,400 shares | |
| 4 | Wells Fargo Securities, LLC | 12.00% | 1,029,600 shares |
Ratio = institution commitment ÷ complete source-table total (8,580,000 shares) × 100.
Underwriting terms
| Measure | Reported value | Unit |
|---|---|---|
| Underwriting discount per share | $1.05 | $ / share |
| Total underwriting discount | $9,009,000 | $ |
Source and calculation
Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
SEC table 1 row 4; source 3740:6416; SHA256 516f1ebb119c4aa67df5c785f206b2dc0852cd66b0e92bec67216250cfee67cd ↗Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
SEC table 1 row 4; source 3740:6416; SHA256 516f1ebb119c4aa67df5c785f206b2dc0852cd66b0e92bec67216250cfee67cd ↗IPO CAPITAL QUALITY
Basis and evidence
No estimate is substituted for missing offer terms.
Capital quality is not yet quantifiable from the filed terms. IPO177 will calculate it when primary/secondary shares, fees and net proceeds are all disclosed.
Offering structure
| Measure | Reported value | Unit |
|---|---|---|
| Shares offered | 8,580,000 | Shares |
| Offering price | $15 | $ / share |
| Gross offering amount | $128,700,000 | $ |
Source and calculation
Prospectus offering table; stated base scenario and source conditions Figures retain their stated source scenario and conditions.
Prospectus offering table; stated base scenario and source conditions
SEC table 39 row 1; source 112547:112924; SHA256 0d3c87b3bdd813d2e757245b170bb83b88278a976b25373252c13943778a10ac ↗Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
SEC table 1 row 3; source 3740:6416; SHA256 516f1ebb119c4aa67df5c785f206b2dc0852cd66b0e92bec67216250cfee67cd ↗Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
SEC table 1 row 3; source 3740:6416; SHA256 516f1ebb119c4aa67df5c785f206b2dc0852cd66b0e92bec67216250cfee67cd ↗Proceeds and intended uses
| Measure | Reported value | Unit |
|---|---|---|
| Issuer proceeds before expenses | $119,691,000 | $ |
Source and calculation
Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
SEC table 1 row 5; source 3740:6416; SHA256 516f1ebb119c4aa67df5c785f206b2dc0852cd66b0e92bec67216250cfee67cd ↗Dilution and valuation
| Calculation | Shares | Value | Reference |
|---|---|---|---|
| Base post-offer valuation | ≈ 17.5774M | ≈ $263.6608M | |
| Post-offer shares — base/no option | 17,577,386 | — | |
| Post-offer shares — full option | 18,864,386 | — | |
| Capitalization shares — actual | 2,468,193 | — | |
| Capitalization shares — pro forma | 8,497,386 | — | |
| Capitalization shares — pro forma as adjusted | 17,577,386 | — | |
| Shares offered | 8,580,000 | — | |
| Offering price | — | $15 | |
| Gross offering amount | — | $128,700,000 |
Basis and evidence ↗
Prospectus share summary; Common stock to be outstanding immediately after this offering and concurrent private placement; 17,577,386 shares (or 18,864,386 shares, if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
Figures retain their stated source scenario and conditions.
Prospectus share summary; Common stock to be outstanding immediately after this offering and concurrent private placement; 17,577,386 shares (or 18,864,386 shares, if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: full option; no inferred sum, conversion or equity value
Figures retain their stated source scenario and conditions.
Capitalization share count; source stage: actual; Common stock, par value $0.001 per share; 52,000,000 shares authorized, 2,468,193 shares issued and outstanding, actual; 500,000,000 shares authorized, pro forma and pro forma as adjusted; 8,497,386 shares issued and outstanding, pro forma; 17,577,386 shares issued and outstanding, pro forma as adjusted; this stage is not reclassified as an IPO equity-value denominator
Figures retain their stated source scenario and conditions.
Capitalization share count; source stage: pro forma; Common stock, par value $0.001 per share; 52,000,000 shares authorized, 2,468,193 shares issued and outstanding, actual; 500,000,000 shares authorized, pro forma and pro forma as adjusted; 8,497,386 shares issued and outstanding, pro forma; 17,577,386 shares issued and outstanding, pro forma as adjusted; this stage is not reclassified as an IPO equity-value denominator
Figures retain their stated source scenario and conditions.
Capitalization share count; source stage: pro forma as adjusted; Common stock, par value $0.001 per share; 52,000,000 shares authorized, 2,468,193 shares issued and outstanding, actual; 500,000,000 shares authorized, pro forma and pro forma as adjusted; 8,497,386 shares issued and outstanding, pro forma; 17,577,386 shares issued and outstanding, pro forma as adjusted; this stage is not reclassified as an IPO equity-value denominator
Figures retain their stated source scenario and conditions.
Prospectus offering table; stated base scenario and source conditions
Prospectus offering table; stated base scenario and source conditions Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
completion-of-this-offering
Base prospectus offering; cover per-share and total columns
Prospectus share summary; Common stock to be outstanding immediately after this offering and concurrent private placement; 17,577,386 shares (or 18,864,386 shares, if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
Exact input · Offering price: $15
Exact input · Post-offer shares — base/no option: 17,577,386
Prospectus share summary; Common stock to be outstanding immediately after this offering and concurrent private placement; 17,577,386 shares (or 18,864,386 shares, if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: full option; no inferred sum, conversion or equity value
Exact input · Post-offer shares — full option: 18,864,386
completion-of-this-offering
Base prospectus offering; cover per-share and total columns
Prospectus share summary; Common stock to be outstanding immediately after this offering and concurrent private placement; 17,577,386 shares (or 18,864,386 shares, if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
completion-of-this-offering
Base prospectus offering; cover per-share and total columns
Prospectus share summary; Common stock to be outstanding immediately after this offering and concurrent private placement; 17,577,386 shares (or 18,864,386 shares, if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
Prospectus share summary; Common stock to be outstanding immediately after this offering and concurrent private placement; 17,577,386 shares (or 18,864,386 shares, if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
Base prospectus offering; cover per-share and total columns
Prospectus share summary; Common stock to be outstanding immediately after this offering and concurrent private placement; 17,577,386 shares (or 18,864,386 shares, if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
Exact input · Post-offer shares — base/no option: 17,577,386
Exact input · Offering price: $15
Share-count comparison
A compatible whole-issuer pre-offer share count is missing; existing-holder or offered-share allocations cannot substitute for it.
Source ↗IPO valuation scenario simulator
Offering completion · $15 × ≈ 17.5774M shares · Final
Source and calculation ↗
Reported point prices retain their security, class, currency and per-security unit; range endpoints remain separate.
Reported whole-issuer base counts retain explicit option, conversion and surrender assumptions.
Equity value is the exact product of the selected compatible per-share price and whole-issuer post-offer count.
A compatible whole-issuer pre-offer share count is missing; existing-holder or offered-share allocations cannot substitute for it.
Each reported full-option, actual, diluted or class-specific case remains independent; no class sum or cross-date substitution is inferred.
The exact selected base supports transparent hypothetical price/share changes; it is not a forecast or tradable float.
The current source URL, accession, hash, proof variants, footnotes, input IDs and executable formulas remain attached. Missing source dates and precision gaps remain explicit.
These saved displays are not verified valuation inputs. Their stage, precision and assumptions have not been established by the current source.
IPO price · 8.580M · $128.70M · $15.00
Latest shares outstanding · 18.86M · $643.84M · Market snapshot
Revenue reference · — · $36.28M · +86.7%
Net-result reference · — · $(35.73M) · Loss-making
$15 × 17,577,386 = $263,660,790 [summary-table-42-base-1-price, summary-table-42-base-1-post]
Exact calculation · Derived whole-issuer equity value: $263,660,790
Sources and calculation notes
Read this report’s SEC filing ↗
| View | Source basis |
|---|---|
| Ownership across stages | Comparable ownership figures across stages are unavailable in this report. See Control for holdings on their disclosed basis. Open filing ↗ |
Latest available filing
- Economic
- ~45.5%*
- As of
- 2026/07/27
Relationship filters
Select for details · Scribe Therapeutics
Holdings and voting rights
Holder groups may overlap; these rows are not an additive ownership partition.
| Holder / measure | Shares | Ownership | Voting rights | Reference |
|---|---|---|---|---|
| Dr. DoudnaOwnership as disclosed | — | >5%Beneficial | — | Source statement; >; source predicate: holds; primary source clause; full source conditions retained; source scope: of our common stock, is one of our co-founders and is a member of our scientific advisory board, and currently serves as professor of Molecular and Cell Biology and Chemistry at UCB; not an additive ownership partition |
| our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliatesOwnership as disclosed | — | approximately 77.4%Beneficial | — | Source statement; approximately ; source predicate: beneficially owned; primary source clause; source condition: assuming no exercise of the underwriters’ option to purchase additional shares, no exercise of our outstanding options and no purchases of shares of common stock in this offering by anyone of this group); source scope: of our voting stock and, upon the completion of this offering and the concurrent private placement, that same group will hold approximately; not an additive ownership partition |
| our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliatesOwnership as disclosed | — | approximately 38.3%Beneficial | — | Source statement; approximately ; source predicate: will hold; primary source clause; source condition: assuming no exercise of the underwriters’ option to purchase additional shares, no exercise of our outstanding options and no purchases of shares of common stock in this offering by anyone of this group); source scope: of our outstanding voting stock (assuming no exercise of the underwriters’ option to purchase additional shares, no exercise of our outstanding options and no purchases of shares of common stock in t; not an additive ownership partition |
| entities with which certain of our directors are affiliatedOwnership as disclosed | — | >5%Beneficial | — | Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding common stock; not an additive ownership partition |
| Benjamin L. Oakes, Ph.D.Beneficial shares | 660,998 | — | — | Number ofSharesBeneficiallyOwned |
| David L. ParrotBeneficial shares | 114,860 | — | — | Number ofSharesBeneficiallyOwned |
| Svetlana Lucas, Ph.D.Beneficial shares | 114,345 | — | — | Number ofSharesBeneficiallyOwned |
| Behzad Aghazadeh, Ph.D.Beneficial shares | 697,650 | — | — | Number ofSharesBeneficiallyOwned |
| Carl L. Gordon, Ph.D., CFABeneficial shares | 348,825 | — | — | Number ofSharesBeneficiallyOwned |
| All executive officers and directors as a group (7 persons)Beneficial shares | 1,936,678 | — | — | Number ofSharesBeneficiallyOwned |
| Entities affiliated with Andreessen HorowitzBeneficial shares | 2,749,392 | — | — | Number ofSharesBeneficiallyOwned |
| Eli Lilly and CompanyBeneficial shares | 1,054,828 | — | — | Number ofSharesBeneficiallyOwned |
| Entities affiliated with Avoro Life Sciences Fund LLCBeneficial shares | 697,650 | — | — | Number ofSharesBeneficiallyOwned |
| Jennifer A. DoudnaBeneficial shares | 603,547 | — | — | Number ofSharesBeneficiallyOwned |
| Brett T. StaahlBeneficial shares | 550,056 | — | — | Number ofSharesBeneficiallyOwned |
| Benjamin L. Oakes, Ph.D.Beneficial ownership | — | 7.61%Beneficial | — | Percentage of SharesBeneficially Owned; BeforeOffering |
| Benjamin L. Oakes, Ph.D.Beneficial ownership | — | 3.72%Beneficial | — | Percentage of SharesBeneficially Owned; AfterOffering |
| David L. ParrotBeneficial ownership | — | 1.33%Beneficial | — | Percentage of SharesBeneficially Owned; BeforeOffering |
| Svetlana Lucas, Ph.D.Beneficial ownership | — | 1.33%Beneficial | — | Percentage of SharesBeneficially Owned; BeforeOffering |
| Behzad Aghazadeh, Ph.D.Beneficial ownership | — | 8.18%Beneficial | — | Percentage of SharesBeneficially Owned; BeforeOffering |
| Behzad Aghazadeh, Ph.D.Beneficial ownership | — | 3.96%Beneficial | — | Percentage of SharesBeneficially Owned; AfterOffering |
| Carl L. Gordon, Ph.D., CFABeneficial ownership | — | 4.09%Beneficial | — | Percentage of SharesBeneficially Owned; BeforeOffering |
| Carl L. Gordon, Ph.D., CFABeneficial ownership | — | 1.98%Beneficial | — | Percentage of SharesBeneficially Owned; AfterOffering |
| All executive officers and directors as a group (7 persons)Beneficial ownership | — | 21.81%Beneficial | — | Percentage of SharesBeneficially Owned; BeforeOffering |
| All executive officers and directors as a group (7 persons)Beneficial ownership | — | 10.78%Beneficial | — | Percentage of SharesBeneficially Owned; AfterOffering |
| Entities affiliated with Andreessen HorowitzBeneficial ownership | — | 32.24%Beneficial | — | Percentage of SharesBeneficially Owned; BeforeOffering |
| Entities affiliated with Andreessen HorowitzBeneficial ownership | — | 15.61%Beneficial | — | Percentage of SharesBeneficially Owned; AfterOffering |
| Eli Lilly and CompanyBeneficial ownership | — | 12.37%Beneficial | — | Percentage of SharesBeneficially Owned; BeforeOffering |
| Eli Lilly and CompanyBeneficial ownership | — | 5.99%Beneficial | — | Percentage of SharesBeneficially Owned; AfterOffering |
| Entities affiliated with Avoro Life Sciences Fund LLCBeneficial ownership | — | 8.18%Beneficial | — | Percentage of SharesBeneficially Owned; BeforeOffering |
| Entities affiliated with Avoro Life Sciences Fund LLCBeneficial ownership | — | 3.96%Beneficial | — | Percentage of SharesBeneficially Owned; AfterOffering |
| Jennifer A. DoudnaBeneficial ownership | — | 7.08%Beneficial | — | Percentage of SharesBeneficially Owned; BeforeOffering |
| Jennifer A. DoudnaBeneficial ownership | — | 3.43%Beneficial | — | Percentage of SharesBeneficially Owned; AfterOffering |
| Brett T. StaahlBeneficial ownership | — | 6.34%Beneficial | — | Percentage of SharesBeneficially Owned; BeforeOffering |
| Brett T. StaahlBeneficial ownership | — | 3.1%Beneficial | — | Percentage of SharesBeneficially Owned; AfterOffering |
| common stockper-share voting rights | — | — | 1 vote per shareVotes per share | Literal source per-share voting entitlement; common stock; subject to the express source qualifications; full source conditions retained; not a holder voting percentage, ownership amount or controller finding; Source capital-stock section applies at the stated completion/consummation stage of this offering; certificate/bylaw effectiveness conditions remain applicable |
Source and calculation ↗
Source statement; >; source predicate: holds; primary source clause; full source conditions retained; source scope: of our common stock, is one of our co-founders and is a member of our scientific advisory board, and currently serves as professor of Molecular and Cell Biology and Chemistry at UCB; not an additive ownership partition
We are party to the UCB Exclusive License Agreement. Dr. Doudna, who holds greater than 5% of our common stock, is one of our co-founders and is a member of our scientific advisory board, and currently serves as professor of Molecular and Cell Biology and Chemistry at UCB. See “Business—Material agreements—UCB—Amended and Restated Exclusive License Agreement” for additional information.
Source statement; approximately ; source predicate: beneficially owned; primary source clause; source condition: assuming no exercise of the underwriters’ option to purchase additional shares, no exercise of our outstanding options and no purchases of shares of common stock in this offering by anyone of this group); source scope: of our voting stock and, upon the completion of this offering and the concurrent private placement, that same group will hold approximately; not an additive ownership partition
Based on the beneficial ownership of our common stock as of July 10, 2026, prior to this offering and the concurrent private placement, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially owned approximately 77.4% of our voting stock and, upon the completion of this offering and the concurrent private placement, that same group will hold approximately 38.3% of our outstanding voting stock (assuming no exercise of the underwriters’ option to purchase additional shares, no exercise of our outstanding options and no purchases of shares of common stock in this offering by anyone of this group). The interests of these stockholders may not be the same as or may even conflict with your interests. For example, these stockholders could delay or prevent a change of control of our Company, even if such a change of control would benefit our other stockholders, which could deprive our stockholders of an opportunity to receive a premium for their common stock as part of a sale of our Company or our assets and might affect the prevailing market price of our common stock. The significant concentration of stock ownership may adversely affect the trading price of our common stock due to investors’ perception that conflicts of interest may exist or arise.
Source statement; approximately ; source predicate: will hold; primary source clause; source condition: assuming no exercise of the underwriters’ option to purchase additional shares, no exercise of our outstanding options and no purchases of shares of common stock in this offering by anyone of this group); source scope: of our outstanding voting stock (assuming no exercise of the underwriters’ option to purchase additional shares, no exercise of our outstanding options and no purchases of shares of common stock in t; not an additive ownership partition
Based on the beneficial ownership of our common stock as of July 10, 2026, prior to this offering and the concurrent private placement, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially owned approximately 77.4% of our voting stock and, upon the completion of this offering and the concurrent private placement, that same group will hold approximately 38.3% of our outstanding voting stock (assuming no exercise of the underwriters’ option to purchase additional shares, no exercise of our outstanding options and no purchases of shares of common stock in this offering by anyone of this group). The interests of these stockholders may not be the same as or may even conflict with your interests. For example, these stockholders could delay or prevent a change of control of our Company, even if such a change of control would benefit our other stockholders, which could deprive our stockholders of an opportunity to receive a premium for their common stock as part of a sale of our Company or our assets and might affect the prevailing market price of our common stock. The significant concentration of stock ownership may adversely affect the trading price of our common stock due to investors’ perception that conflicts of interest may exist or arise.
Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding common stock; not an additive ownership partition
In connection with our Series B Preferred Stock financing, we entered into the IRA with certain holders of our redeemable convertible preferred stock, including entities with which certain of our directors are affiliated and who hold more than 5% of our outstanding common stock. Under the IRA, these stockholders are entitled to rights with respect to the registration of their shares under the Securities Act following this offering and the provisions relating to registration rights included in the IRA will not terminate as a result of this offering. See the section titled “Description of Capital Stock—Registration rights” for additional information.
Exact source ownership column: Number ofSharesBeneficiallyOwned; holders may overlap; not an additive partition
Raw source column: Number ofSharesBeneficiallyOwned; source holder: Benjamin L. Oakes, Ph.D.(1)
Exact source ownership column: Number ofSharesBeneficiallyOwned; holders may overlap; not an additive partition
Raw source column: Number ofSharesBeneficiallyOwned; source holder: David L. Parrot(2)
Exact source ownership column: Number ofSharesBeneficiallyOwned; holders may overlap; not an additive partition
Raw source column: Number ofSharesBeneficiallyOwned; source holder: Svetlana Lucas, Ph.D.(3)
Exact source ownership column: Number ofSharesBeneficiallyOwned; holders may overlap; not an additive partition
Raw source column: Number ofSharesBeneficiallyOwned; source holder: Behzad Aghazadeh, Ph.D.(4)
Exact source ownership column: Number ofSharesBeneficiallyOwned; holders may overlap; not an additive partition
Raw source column: Number ofSharesBeneficiallyOwned; source holder: Carl L. Gordon, Ph.D., CFA(5)
Exact source ownership column: Number ofSharesBeneficiallyOwned; holders may overlap; not an additive partition
Raw source column: Number ofSharesBeneficiallyOwned; source holder: All executive officers and directors as a group (7 persons)(7)
Exact source ownership column: Number ofSharesBeneficiallyOwned; holders may overlap; not an additive partition
Raw source column: Number ofSharesBeneficiallyOwned; source holder: Entities affiliated with Andreessen Horowitz(8)
Exact source ownership column: Number ofSharesBeneficiallyOwned; holders may overlap; not an additive partition
Raw source column: Number ofSharesBeneficiallyOwned; source holder: Eli Lilly and Company(9)
Exact source ownership column: Number ofSharesBeneficiallyOwned; holders may overlap; not an additive partition
Raw source column: Number ofSharesBeneficiallyOwned; source holder: Entities affiliated with Avoro Life Sciences Fund LLC(4)
Exact source ownership column: Number ofSharesBeneficiallyOwned; holders may overlap; not an additive partition
Raw source column: Number ofSharesBeneficiallyOwned; source holder: Jennifer A. Doudna(10)
Exact source ownership column: Number ofSharesBeneficiallyOwned; holders may overlap; not an additive partition
Raw source column: Number ofSharesBeneficiallyOwned; source holder: Brett T. Staahl(11)
Exact source ownership column: Percentage of SharesBeneficially Owned; BeforeOffering; holders may overlap; not an additive partition
Raw source column: Percentage of SharesBeneficially Owned; BeforeOffering; source holder: Benjamin L. Oakes, Ph.D.(1)
Exact source ownership column: Percentage of SharesBeneficially Owned; AfterOffering; holders may overlap; not an additive partition
Raw source column: Percentage of SharesBeneficially Owned; AfterOffering; source holder: Benjamin L. Oakes, Ph.D.(1)
Exact source ownership column: Percentage of SharesBeneficially Owned; BeforeOffering; holders may overlap; not an additive partition
Raw source column: Percentage of SharesBeneficially Owned; BeforeOffering; source holder: David L. Parrot(2)
Exact source ownership column: Percentage of SharesBeneficially Owned; BeforeOffering; holders may overlap; not an additive partition
Raw source column: Percentage of SharesBeneficially Owned; BeforeOffering; source holder: Svetlana Lucas, Ph.D.(3)
Exact source ownership column: Percentage of SharesBeneficially Owned; BeforeOffering; holders may overlap; not an additive partition
Raw source column: Percentage of SharesBeneficially Owned; BeforeOffering; source holder: Behzad Aghazadeh, Ph.D.(4)
Exact source ownership column: Percentage of SharesBeneficially Owned; AfterOffering; holders may overlap; not an additive partition
Raw source column: Percentage of SharesBeneficially Owned; AfterOffering; source holder: Behzad Aghazadeh, Ph.D.(4)
Exact source ownership column: Percentage of SharesBeneficially Owned; BeforeOffering; holders may overlap; not an additive partition
Raw source column: Percentage of SharesBeneficially Owned; BeforeOffering; source holder: Carl L. Gordon, Ph.D., CFA(5)
Exact source ownership column: Percentage of SharesBeneficially Owned; AfterOffering; holders may overlap; not an additive partition
Raw source column: Percentage of SharesBeneficially Owned; AfterOffering; source holder: Carl L. Gordon, Ph.D., CFA(5)
Exact source ownership column: Percentage of SharesBeneficially Owned; BeforeOffering; holders may overlap; not an additive partition
Raw source column: Percentage of SharesBeneficially Owned; BeforeOffering; source holder: All executive officers and directors as a group (7 persons)(7)
Exact source ownership column: Percentage of SharesBeneficially Owned; AfterOffering; holders may overlap; not an additive partition
Raw source column: Percentage of SharesBeneficially Owned; AfterOffering; source holder: All executive officers and directors as a group (7 persons)(7)
Exact source ownership column: Percentage of SharesBeneficially Owned; BeforeOffering; holders may overlap; not an additive partition
Raw source column: Percentage of SharesBeneficially Owned; BeforeOffering; source holder: Entities affiliated with Andreessen Horowitz(8)
Exact source ownership column: Percentage of SharesBeneficially Owned; AfterOffering; holders may overlap; not an additive partition
Raw source column: Percentage of SharesBeneficially Owned; AfterOffering; source holder: Entities affiliated with Andreessen Horowitz(8)
Exact source ownership column: Percentage of SharesBeneficially Owned; BeforeOffering; holders may overlap; not an additive partition
Raw source column: Percentage of SharesBeneficially Owned; BeforeOffering; source holder: Eli Lilly and Company(9)
Exact source ownership column: Percentage of SharesBeneficially Owned; AfterOffering; holders may overlap; not an additive partition
Raw source column: Percentage of SharesBeneficially Owned; AfterOffering; source holder: Eli Lilly and Company(9)
Exact source ownership column: Percentage of SharesBeneficially Owned; BeforeOffering; holders may overlap; not an additive partition
Raw source column: Percentage of SharesBeneficially Owned; BeforeOffering; source holder: Entities affiliated with Avoro Life Sciences Fund LLC(4)
Exact source ownership column: Percentage of SharesBeneficially Owned; AfterOffering; holders may overlap; not an additive partition
Raw source column: Percentage of SharesBeneficially Owned; AfterOffering; source holder: Entities affiliated with Avoro Life Sciences Fund LLC(4)
Exact source ownership column: Percentage of SharesBeneficially Owned; BeforeOffering; holders may overlap; not an additive partition
Raw source column: Percentage of SharesBeneficially Owned; BeforeOffering; source holder: Jennifer A. Doudna(10)
Exact source ownership column: Percentage of SharesBeneficially Owned; AfterOffering; holders may overlap; not an additive partition
Raw source column: Percentage of SharesBeneficially Owned; AfterOffering; source holder: Jennifer A. Doudna(10)
Exact source ownership column: Percentage of SharesBeneficially Owned; BeforeOffering; holders may overlap; not an additive partition
Raw source column: Percentage of SharesBeneficially Owned; BeforeOffering; source holder: Brett T. Staahl(11)
Exact source ownership column: Percentage of SharesBeneficially Owned; AfterOffering; holders may overlap; not an additive partition
Raw source column: Percentage of SharesBeneficially Owned; AfterOffering; source holder: Brett T. Staahl(11)
Literal source per-share voting entitlement; common stock; subject to the express source qualifications; full source conditions retained; not a holder voting percentage, ownership amount or controller finding; Source capital-stock section applies at the stated completion/consummation stage of this offering; certificate/bylaw effectiveness conditions remain applicable
Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders. We have not provided for cumulative voting for the election of directors in our amended and restated certificate of incorporation, which means that holders of a majority of the shares of our common stock will be able to elect all of our directors. Our amended and restated certificate of incorporation will establish a classified board of directors, to be divided into three classes with staggered three-year terms. Only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms. Source context: The following description summarizes the most important terms of our capital stock, as will be in effect following this offering. Because it is only a summary, it does not contain all the information that may be important to you. We expect to adopt an amended and restated certificate of incorporation and amended and restated bylaws that will become effective upon the completion of this offering, and this description summarizes provisions that are expected to be included in these documents. For a complete description, you should refer to our amended and restated certificate of incorporation and amended and restated bylaws, which are included as exhibits to the registration statement of which this prospectus forms a part, and to the applicable provisions of Delaware law.
Saved control snapshot
The dated saved report retains its own figures and assumptions. These strings are not new calculation inputs.
| Holder / measure | Shares | Ownership | Voting rights | Reference |
|---|---|---|---|---|
| Existing holdersMajor ownership group | — | ~54.5%* | — | |
| Other disclosed classesMajor ownership group | — | See filing | — | |
| IPO sharesPublic / new investors | — | 8.580M | — |
Economic ownership
A chart needs complete, non-overlapping economic interests on one date and share basis. The disclosed holder figures remain in the table.
IPO shares are immediately tradable; later supply depends on the final lock-up, option and resale-registration terms.
- Initial float
- 8.580M
- Restricted / potential supply
- 18.86M
- Multiple
- See filing
- Increase
- See filing
Share supply
Source lock-up conditions
Literal day restriction; after date of this prospectus; full conditions and exceptions remain in the source paragraph
| Measure | Reported value |
|---|---|
| our directors and officers and substantially all of our security holders are, orAfter date of this prospectus · Source conditions apply | 180 days |
| We, our executive officers and directors and holders of substantially all of our existing securitiesAfter date of this prospectus · Source conditions apply | 180 days |
| Each of our officers, directors and holders of substantially all of our outstanding equity securitiesAfter date of this prospectus · Source conditions apply | 180 days |
Source and calculation
All of our directors and officers and substantially all of our security holders are, or will be, subject to lock-up agreements or market standoff provisions that prohibit them from offering for sale, selling, contracting to sell, granting any option for the sale of, transferring or otherwise disposing of any shares of our common stock or options to acquire shares of our common stock or any security or instrument related to our common stock, or entering into any swap, hedge or other arrangement that transfers any of the economic consequences of ownership of our common stock, for a period of 180 days following the date of this prospectus without the prior written consent of Leerink Partners LLC and Goldman Sachs & Co. LLC, subject to certain exceptions. See the section titled “Underwriting” for additional information.
SEC lock-up paragraph; source 1643637:1644636; SHA256 314a0befc98c84429b65c8aa0c706f68bafb9739131e38087b4c278a31dff155 ↗We, our executive officers and directors and holders of substantially all of our existing securities have agreed not to sell or transfer any common stock or securities convertible into or exchangeable or exercisable for common stock, for 180 days after the date of this prospectus without first obtaining the written consent of Leerink Partners LLC and Goldman Sachs & Co. LLC on behalf of the underwriters.
SEC lock-up paragraph; source 1699966:1700493; SHA256 a497b1ef61a825fbfff0e097846262fda841885aeabda2351b528c88d6909ee4 ↗Based on the shares outstanding as of March 31, 2026, upon completion of this offering and the concurrent private placement, we will have a total of 17,577,386 shares of common stock outstanding. Of these shares, only the 8,580,000 shares of common stock sold in this offering, or 9,867,000 shares if the underwriters exercise their option to purchase additional shares in full, will be freely tradable, without restriction, in the public market immediately after this offering. Each of our officers, directors and holders of substantially all of our outstanding equity securities have entered into lock-up agreements with the underwriters that restrict their ability to sell or transfer their shares. The lock-up agreements pertaining to this offering will expire 180 days from the date of this prospectus. However, Leerink Partners LLC and Goldman Sachs & Co. LLC may, in their sole discretion, permit our officers, directors and other current stockholders who are subject to the contractual lock-up to sell shares prior to the expiration of the lock-up agreements. After the lock-up agreements expire, the shares of common stock subject to these lock-up agreements will be eligible for sale in the public market, unless held by our officers, directors and their affiliated entities, in which case such shares will be subject to volume limitations under Rule 144 under the Securities Act of 1933, as amended, or the Securities Act.
SEC lock-up paragraph; source 618460:620278; SHA256 92726650421e535b833ff2e1cc0d096ea49007a265ab993e2bc5ef3b60d2afcc ↗Conditional lock-up timeline
Conditional lock-up timeline
Eligibility is not a sale. Release conditions, holder groups and exceptions remain separate.
Milestones and unconfirmed releases
| Holder / event | Term / date | Conditions |
|---|---|---|
| Over-allotment window | Post-listing See filing · Additional shares only if exercised | Over-allotment window · Additional shares only if exercised |
| Insider resale eligibility | Holder-specific See 424B · Existing-holder supply | Insider resale eligibility · Existing-holder supply |
Basis and evidence
Over-allotment window · Additional shares only if exercised
Lock-up / shares eligible for future sale ↗Insider resale eligibility · Existing-holder supply
Lock-up / shares eligible for future sale ↗Financial quality
Bars compare absolute amounts within each measure. Each measure has its own scale.
Net income / (loss)
$ · Annual values as reportedOperating cash flow
$ · Annual values as reported| Calculation | FY2024 | FY2025 |
|---|---|---|
| Net income / (loss) | ($47,786,000) | ($21,808,000) |
| Operating cash flow | ($45,235,000) | ($45,213,000) |
| Calculation | Reported value |
|---|---|
| Cash and cash equivalents2024-12-31 | $12,602,000 |
| Cash and cash equivalents2025-12-31 | $12,796,000 |
| Current assets2024-12-31 | $110,374,000 |
| Current assets2025-12-31 | $66,934,000 |
| Total assets2024-12-31 | $127,971,000 |
| Total assets2025-12-31 | $78,219,000 |
| Current liabilities2024-12-31 | $35,019,000 |
| Current liabilities2025-12-31 | $69,057,000 |
| Total liabilities2024-12-31 | $133,474,000 |
| Total liabilities2025-12-31 | $101,282,000 |
| Total equity / (deficit)2024-12-31 | ($125,859,000) |
| Total equity / (deficit)2025-12-31 | ($143,419,000) |
| General and administrative expensesFY2024 | $13,163,000 |
| General and administrative expensesFY2025 | $16,449,000 |
| Cash and cash equivalents2025-12-31 · Unaudited | $12,796,000 |
| Cash and cash equivalents2026-03-31 · Unaudited | $20,381,000 |
| Current assets2025-12-31 · Unaudited | $66,934,000 |
| Current assets2026-03-31 · Unaudited | $52,399,000 |
| Total assets2025-12-31 · Unaudited | $78,219,000 |
| Total assets2026-03-31 · Unaudited | $65,208,000 |
| Current liabilities2025-12-31 · Unaudited | $69,057,000 |
| Current liabilities2026-03-31 · Unaudited | $79,720,000 |
| Total liabilities2025-12-31 · Unaudited | $101,282,000 |
| Total liabilities2026-03-31 · Unaudited | $103,590,000 |
| Total equity / (deficit)2025-12-31 · Unaudited | ($143,419,000) |
| Total equity / (deficit)2026-03-31 · Unaudited | ($158,738,000) |
| General and administrative expenses3M ended 2025-03-31 · Unaudited | $6,691,000 |
| General and administrative expenses3M ended 2026-03-31 · Unaudited | $3,355,000 |
| Net income / (loss)3M ended 2025-03-31 · Unaudited | ($3,425,000) |
| Net income / (loss)3M ended 2026-03-31 · Unaudited | ($17,347,000) |
| Operating cash flow3M ended 2025-03-31 · Unaudited | ($13,621,000) |
| Operating cash flow3M ended 2026-03-31 · Unaudited | ($7,555,000) |
Basis and evidence
Saved snapshot — period not verified
These saved figures have no verified reporting period or currency basis. They are excluded from statement comparisons and calculations.
Financial quality
| Calculation | Reported value | Reference |
|---|---|---|
| Revenue | $36.28M | +86.7% |
| Net result | $(35.73M) | Latest reported |
| Market-value reference | $643.84M | Post-listing snapshot |
| Shares outstanding | 18.86M | Latest reported |
| Offer size | $128.70M | 8.580M |
Sources and calculation notes
Read this report’s SEC filing ↗
| View | Source basis |
|---|---|
| Financial review | Reported financial figures are shown above. A cash-runway estimate needs compatible cash-flow and funding assumptions. Open filing ↗ |
Baseline filing — comparison pending
No source-comparable material changes identified in this report.
Why it mattersChanges dilution, public float and potential supply.
Evidence · 424B4 · 2026/07/27Why it mattersChanges valuation, proceeds and first-day return assumptions.
Evidence · 424B4 · 2026/07/27424B4
• Final prospectus source verified
• Trading began on 2026-07-24 at $15.00
Clinical development, regulatory approval and cash-runway outcomes can change the equity value materially.
- Potential impact
- High
- Evidence
- 424B4 · 2026/07/27 ↗
The latest reported period remains loss-making.
- Potential impact
- High
- Evidence
- 424B4 · 2026/07/27 ↗
The primary-secondary mix, controlling holders and voting rights require the final beneficial-ownership table.
- Potential impact
- High
- Evidence
- 424B4 · 2026/07/27 ↗
Option exercise, employee equity and lock-up expiry can expand tradable supply.
- Potential impact
- Medium
- Evidence
- 424B4 · 2026/07/27 ↗
Sources and calculation notes
Final prospectus, offer price, listing date and headline financial evidence reconciled
View the filing's actual first page +
